BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28362884)

  • 1. Utility of the Aspirin and P2Y12 Response Assays to Determine the Effect of Antiplatelet Agents on Platelet Reactivity in Traumatic Brain Injury.
    Parry PV; Choi PA; Bauer JS; Panczykowski DM; Puccio AM; Okonkwo DO
    Neurosurgery; 2017 Jan; 80(1):92-96. PubMed ID: 28362884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Aspirin and P2Y12 Response Assays in Detecting Reversal of Platelet Inhibition With Platelet Transfusion in Patients With Traumatic Brain Injury on Antiplatelet Therapy.
    Choi PA; Parry PV; Bauer JS; Zusman BE; Panczykowski DM; Puccio AM; Okonkwo DO
    Neurosurgery; 2017 Jan; 80(1):98-104. PubMed ID: 28362883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia.
    Clavijo LC; Al-Asady N; Dhillon A; Matthews RV; Caro J; Tun H; Rowe V; Shavelle DM
    Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):516-520. PubMed ID: 29221961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response.
    Good RI; McGarrity A; James TE; Miller H; McConnachie A; Goodall AH; Oldroyd KG
    Thromb Res; 2015 Jun; 135(6):1140-6. PubMed ID: 25746368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
    Angiolillo DJ; Jakubowski JA; Ferreiro JL; Tello-Montoliu A; Rollini F; Franchi F; Ueno M; Darlington A; Desai B; Moser BA; Sugidachi A; Guzman LA; Bass TA
    J Am Coll Cardiol; 2014 Sep; 64(10):1005-14. PubMed ID: 25190236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
    Dillinger JG; Saeed A; Spagnoli V; Sollier CB; Sideris G; Silberman SM; Voicu S; Drouet L; Henry P
    Thromb Res; 2016 Aug; 144():56-61. PubMed ID: 27289074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.
    Jeong YH; Bliden KP; Antonino MJ; Park KS; Tantry US; Gurbel PA
    Am Heart J; 2012 Jul; 164(1):35-42. PubMed ID: 22795280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures.
    Nakagawa I; Park HS; Yokoyama S; Wada T; Hironaka Y; Motoyama Y; Takayama K; Kichikawa K; Nakase H
    J Stroke Cerebrovasc Dis; 2016 Jan; 25(1):163-71. PubMed ID: 26493334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2Y
    Kim CH; Hwang G; Kwon OK; Ban SP; Chinh ND; Tjahjadi M; Oh CW; Bang JS; Kim T
    Radiology; 2017 Feb; 282(2):542-551. PubMed ID: 27603789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between silent embolic cerebral infarction and continuous increase of P2Y12 reaction units after neurovascular stenting.
    Kim BJ; Kwon JY; Jung JM; Lee DH; Kang DW; Kim JS; Kwon SU
    J Neurosurg; 2014 Oct; 121(4):891-8. PubMed ID: 25036195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.